Physician profile
Robert M Sims
NPI 1437152931
$11,526.44
in general payments reported to CMS, 2019-2025
50 companies · $1,202 in 2025
The $1,202 reported for 2025 was more than what 89% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,451 · 2020: $1,307 · 2021: $1,689 · 2022: $1,821 · 2023: $2,193 · 2024: $1,863 · 2025: $1,202.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,258.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,258.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,493.84 | 2019-2025 | Vraylar, Ubrelvy, Qulipta |
| Amgen INC. | $1,350.58 | 2019-2025 | Evenity, Prolia, Repatha |
| Pfizer INC. | $1,004.92 | 2019-2025 | |
| Novo Nordisk INC | $990.21 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Janssen Pharmaceuticals, INC | $822.90 | 2019-2024 | Xarelto |
| Astrazeneca Pharmaceuticals Lp | $809.81 | 2019-2025 | Breztri, Airsupra, Fasenra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $549.88 | 2019-2025 | Jardiance |
| Glaxosmithkline, LLC. | $497.88 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Lilly USA, LLC | $328.47 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $296.69 | 2021-2025 | |
| Novartis Pharmaceuticals Corporation | $259.50 | 2019-2024 | |
| Allergan, INC. | $259.39 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $248.65 | 2019-2025 | Capvaxive, Gardasil 9, Vaxneuvance |
| Otsuka America Pharmaceutical, INC. | $218.88 | 2023-2025 | Rexulti, Nuedexta |
| Astellas Pharma US INC | $208.87 | 2019-2025 | Veozah |
Show all 50 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Sims listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.